You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. HT-production of Abs using Interaction Trap in Yeast

    SBC: AFFOMIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Affomix would like to commercialize antibody chips to enable researchers to study the human proteome. Currently, researchers use gene chips as a surrogate means to estimate the concentration of the vast variety of pro teins in cells and tissues. But given the choice, most researchers would prefer to study the proteins directly because of the; i) poor correla ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Huperzine for Cognitive and Functional Impairment in Schizophrenia

    SBC: BIOMEDISYN CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Schizophrenia affects approximately 3 million people in the US, and it is one of the leading causes of disability. Currently available drugs are only partially effective, particularly for the cognitive impairments that contribute to functional loss. A new investigational drug, BMD-101, has been shown to have neuroprotective, neurotrophic, cholinergic, and dopa ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Use of hyaluronan for treatment of chemotherapy sequelae

    SBC: CASCADE LIFESCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Among the most undesirable sequelae of chemo- and radiotherapies for the treatment of cancer are bone marrow hypoplasia and pancytopenia. These can further lead to immunodeficiency, bleeding and hypoxia significantly i mpacting the morbidity of cancer patients. The discovery of growth factors that regulate hematopoietic stem cells (HSC) proliferation led to th ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Minimally-Invasive Image-Guided Therapy for Cancer Treatment

    SBC: CONTRADYN, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term objective of this research is to develop a technology and eventually a minimally-invasive commercial system for image-guided photodynamic therapy for cancer. This is certainly in keeping with NCI's focus o n imaging in vivo for cancer screening, diagnosis, progression, image-guide therapy, treatment monitoring, and recurrence. In studies conducted ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Computer-Delivered Interventions for Secondhand Smoke Exposure

    SBC: EMERALD CITY ENTERTAINMENT GROUP, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Close to 40% of US children are exposed to secondhand tobacco smoke (SHS) in homes and up to 50% in cars, compromising the health and lives of millions of children. More effective, inexpensive, and accessible interventi ons are needed that impact parents' and caregivers' willingness and ability to institute smoking restrictions. We propose the development of an ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  6. Delivery system development for a reservoir targeted Lyme disease vaccine

    SBC: FoodSource Lure Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): The incidence and geographic distribution of Lyme disease in the U.S. has increased steadily since its first description in 1977. Efforts to stem the spread of the disease through controlling the population of its tick vector and/or the mouse reservoirs of the disease have met with only limited success. The only approved human vaccine to protect against Lyme d ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  7. Detection of Non-Human Sialic Acid in Biotherapeutic Applications

    SBC: GCFREE, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): GcFree, Inc. is founded on recent discoveries and patents about a sialic acid called Neu5Gc, which is present in large amounts on the surface of cells of most animals, but not humans. Potentially immunogenic Neu5Gc from exogenous sources (e.g., animal- derived reagents used for making biotherapeutic products) are taken up by human cells and expressed on their ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  8. The Development of Cross-Platform Quantitative Standards for Diagnostic Immunohis

    SBC: HISTORX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Patient-specific therapies targeted to the phenotype of individual tumors represent the future of cancer treatment. The prototypes for this type of therapy are Herceptin and Tamoxifen, which are only given to patients e xpressing a particular level of HER2 and estrogen receptor (ER), respectively. It is likely that dozens of such therapies will be developed for ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  9. HCV Genotyping and Drug Resistance Testing by ESI/MS

    SBC: IBIS BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Persistent infections with hepatitis C virus (HCV) are a major public health concern in the United States today. While diagnostic tests exist to identify and quantify HCV infections, there is a great need for analytical methods that provide detailed information about the molecular nature of HCV infections. HCV infections are marked by considerable genetic dive ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Snapback Primers for Genotyping and Mutation Scanning

    SBC: IDAHO TECHNOLOGY            Topic: N/A

    DESCRIPTION (provided by applicant): The objective of this Fast-Track STTR is to develop a simple, inexpensive, closed-tube PCR method for genotyping and sequence variant scanning. Instead of covalently-labeled probes, one of two primers includes a tail w ith a probe element. After asymmetric PCR, this tail anneals internally to the same strand, snapping back , to form a stem/loop structure. Bot ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government